VMAT 2 Antibody (D-4): sc-390285

VMAT 2 Antibody (D-4) is a mouse monoclonal IgG1 antibody that detects VMAT 2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). VMAT 2, or vesicular monoamine transporter 2, plays a crucial role in the regulation of neurotransmission by facilitating the packaging of monoamines into synaptic vesicles, which is essential for the proper release of neurotransmitters in the nervous system. VMAT 2 is primarily located in the presynaptic terminals of neurons, where VMAT 2 ensures that neurotransmitters like dopamine, serotonin, and norepinephrine are stored and released in a controlled manner. Precise localization of VMAT 2 is vital, as VMAT 2 directly influences synaptic transmission and, consequently, various physiological processes, including mood regulation, motor control, and reward pathways. Dysregulation of VMAT 2 has been implicated in several neuropsychiatric disorders, making VMAT 2 a significant target for research and therapeutic interventions. Anti-VMAT 2 antibody (D-4) is an invaluable tool for studying the dynamics of neurotransmitter release and the underlying mechanisms of related diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VMAT 2 Antibody (D-4) References:

1. Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line--an experimental cell model for dopamine toxicity studies.  |  Fuentes, P., et al. 2007. Chem Res Toxicol. 20: 776-83. PMID: 17425337
2. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.  |  Gopalakrishnan, A., et al. 2007. Mol Pharmacol. 72: 1567-75. PMID: 17766642
3. Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.  |  Muñoz, P., et al. 2012. Biochim Biophys Acta. 1822: 1125-36. PMID: 22483869
4. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.  |  Podurgiel, SJ., et al. 2013. Neuroscience. 250: 507-19. PMID: 23867769
5. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.  |  Nunes, EJ., et al. 2013. J Neurosci. 33: 19120-30. PMID: 24305809
6. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.  |  Randall, PA., et al. 2014. PLoS One. 9: e99320. PMID: 24937131
7. The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.  |  Yohn, SE., et al. 2015. Psychopharmacology (Berl). 232: 1313-23. PMID: 25323625
8. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.  |  Podurgiel, SJ., et al. 2016. Behav Brain Res. 298: 188-91. PMID: 26590367
9. Oral Ingestion and Intraventricular Injection of Curcumin Attenuates the Effort-Related Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Motivational Symptoms of Depression.  |  Yohn, SE., et al. 2017. J Nat Prod. 80: 2839-2844. PMID: 28905625
10. Lack of Support for the Use of VMAT-2 Inhibitors for the Treatment of Tics in Tourette Syndrome.  |  Baron, MS. 2021. JAMA Netw Open. 4: e2129704. PMID: 34661669

The preferred VMAT 2 antibody is VMAT 2 Antibody (H-12): sc-374079.